Results 111 to 120 of about 15,701 (194)

Sex-specific modulation of gut microbiota by empagliflozin contributes to renoprotection in diabetic kidney disease mice. [PDF]

Front Microbiol
He J, Liu J, Zhang H, Wang Y.
europepmc   +1 more source

Immune Dysregulation in Branched Chain Organic Acidemias

Journal of Inherited Metabolic Disease, Volume 49, Issue 4, July 2026.
ABSTRACT Organic acidemias (OAs) are a group of inherited disorders, most commonly caused by defects in mitochondrial enzymes involved in amino acid and fatty acid metabolism. While they characteristically present with metabolic and neurological crises, growing evidence reveals a significant burden of chronic immune dysregulation in some disorders and ...
Abdul L. Shakerdi, Jack Drda, Justin A. Dutta, Jerry Vockley   +3 more
wiley   +1 more source

Empagliflozin and renal histological changes in an experimental model of heart failure in male rats. [PDF]

Physiol Rep
Wisnivesky ACT, Bertacchi JGF, Caramelli B.   +2 more
europepmc   +1 more source

A Systematic Review and Expert Evaluation of Perioperative SGLT2 Inhibitor‐Associated Ketoacidosis Case Reports

Acta Anaesthesiologica Scandinavica, Volume 70, Issue 6, July 2026.
ABSTRACT Introduction The use of sodium–glucose cotransporter‐2 inhibitors (SGLT2i) in the perioperative setting may lead to SGLT2i‐associated postoperative ketoacidosis (SAPKA) in patients with type 2 diabetes (T2D). Therefore, cessation of this drug is recommended before surgery.
L. I. P. Snel, X. Li, F. Jamaludin, S. E. Siegelaar, F. Holleman, T. M. Vriesendorp, J. H. DeVries, J. B. L. Hoekstra, B. Preckel, D. H. van Raalte, J. Hermanides, A. H. Hulst   +11 more
wiley   +1 more source

Effectiveness of a Psychiatrist‐Led Clinic for Metabolic Health in Severe Mental Illness: A Retrospective Chart Review Study

Acta Psychiatrica Scandinavica, Volume 154, Issue 1, Page 74-88, July 2026.
ABSTRACT Background Psychotropic medications are associated with serious metabolic adverse effects, which contribute to an increased risk of cardiometabolic comorbidities in patients with severe mental illness (SMI). Several intervention strategies are available to mitigate these metabolic adverse effects; however, data on their utility in real‐world ...
Nicolette Stogios, Femin Prasad, Riddhita De, Kateryna Maksyutynska, Akash PrasannaKumar, Vittal Korann, Tariq Ahmed, Marcos Sanches, Leah Burton, Mohammed A. Alarabi, Tanner Isinger, Michelle Desanti, Rebecca Oliveira, Daphne J. Korczak, Ariel Graff‐Guerrero, Gary Remington, Margaret K. Hahn, Sri Mahavir Agarwal   +17 more
wiley   +1 more source

Research Progress of SGLT2 Inhibitors in the Treatment of Acute Heart Failure: A Narrative Review. [PDF]

Int J Gen Med
Wang X, Ning Y, Wang X, Li G, Wang X, Wu D.   +5 more
europepmc   +1 more source

A systematic review and meta‐analysis of the relative benefit of dual versus single oral hypoglycaemic therapy following diagnosis with type 2 diabetes (T2D)

Diabetic Medicine, Volume 43, Issue 7, July 2026.
Abstract Introduction Achieving and sustaining target glycated haemoglobin (HbA1c) levels is fundamental in the management of type 2 diabetes (T2D). We here aimed to assess whether initial dual oral therapy outperforms monotherapy in reaching glycaemic targets in patients with treatment‐naive or early‐stage T2D.
Mairead Kelly, Sushant Saluja, Hugh Logan Ellis, Sarah Jamil, Martin B. Whyte, Adrian Heald   +5 more
wiley   +1 more source

Association of SGLT2 Inhibitor With Stroke in Type 2 Diabetes With Diabetic Retinopathy: A Multicenter Electronic Health Record Data Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 5614-5626, July 2026.
ABSTRACT Aims Diabetic retinopathy (DR) is linked to elevated risks of cerebrovascular diseases. Whether sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) reduce stroke risk in patients with type 2 diabetes (T2D) and DR remains uncertain. Materials and Methods We conducted a retrospective cohort study using the TriNetX Research Network.
Kuo‐En Chen, Po‐Chun Wang, Hui‐An Lin, Sheng‐Feng Lin   +3 more
wiley   +1 more source

Outcomes With Finerenone by Baseline Treatment Goals in Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Analysis

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 6022-6033, July 2026.
ABSTRACT Aims The American Diabetes Association recommends achieving treatment goals (glycated haemoglobin ≤ 53 mmol/mol [7.0%], blood pressure < 130/80 mmHg, low‐density lipoprotein cholesterol < 1.81 mmol/L and use of sodium–glucose cotransporter‐2 inhibitors or glucagon‐like peptide‐1 receptor agonists), to reduce cardiovascular and kidney ...
João Sérgio Neves, Ana Rita Leite, Francisco Vasques‐Nóvoa, Bertram Pitt, Gerasimos Filippatos, Luis M. Ruilope, Peter Rossing, Stefan D. Anker, Gianluigi Savarese, Charlie A. B. Scott, Andrea Lage, Meike D. Brinker, João Pedro Ferreira   +12 more
wiley   +1 more source

Cardiovascular protection by SGLT2 inhibitors: an integrative review of mechanistic networks, clinical evidence, and safety considerations. [PDF]

Front Cardiovasc Med
Wang Z, Wang Y, Shangguan W, Li T.
europepmc   +1 more source